Belgium’s Promethera banks $31M for orphan disease R&D

Damian Garde

Biosciences has put together €25.3 million ($ 31.4 million) in equity and loans to hit the gas on its stem cell treatment for rare liver diseases.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS